Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDC-3042 in advanced malignancies
NCT06052852Phase 1Terminated
- Sponsor
- Bolt Biotherapeutics
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BDC-3042 in triple-negative breast cancer (TNBC), clear cell renal cell carcinoma (ccRCC), ovarian cancer and 4 more (2 arms), sponsored by Bolt Biotherapeutics. Primary endpoints: Treatment Emergent Adverse Events at 2 years, Serious Adverse Events at 2 years and 2 more. Started Oct 2023; status: terminated.
02
Drugs
BDC-3042
03
Conditions
triple-negative breast cancer (TNBC)clear cell renal cell carcinoma (ccRCC)ovarian cancerhead and neck cancer (HNC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06052852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052852.